Lawsuit Overview - A lawsuit has been filed against Edwards Lifesciences Corporation and certain senior executives for potential violations of federal securities laws [1] - The lawsuit is pending in the U S District Court for the Central District of California under the case Patel v Edwards Lifesciences Corporation et al No 24-cv-02221 [2] - Investors have until December 13 2024 to ask the Court to be appointed as lead plaintiff [2] Allegations Against Edwards Lifesciences - Edwards Lifesciences is accused of making materially false and misleading statements regarding its TAVR platform and its ability to capitalize on unmet demand [4] - The company allegedly overstated the demand and growth potential of TAVR while its patient activation activities failed to reach the low-treatment-rate population [4] - Healthcare organizations prioritized other treatments over TAVR leading to underutilization despite the company's claims of a significantly undertreated patient population [5] Financial Impact - On July 24 2024 Edwards Lifesciences slashed its guidance for TAVR for fiscal 2024 and announced disappointing financial results for TAVR in fiscal 2Q 24 [5] - The news caused a 31% decline in Edwards stock price from $86 95 per share on July 24 2024 to $59 70 per share on July 25 2024 [6] Company Background - Edwards Lifesciences is an international company that researches develops and provides products and technologies for heart valve repair and replacement therapies as well as critical care monitoring solutions [3] - The company categorizes its therapies and technologies into four segments: Transcatheter Aortic Valve Replacement (TAVR) Transcatheter Mitral and Tricuspid Therapies (TMTT) Surgical Structural Heart therapies and Critical Care therapies [3] Legal Representation - Bleichmar Fonti & Auld LLP is representing plaintiffs in this securities class action and shareholder litigation [8] - The firm has a track record of recovering significant amounts in similar cases including $900 million from Tesla Inc's Board of Directors and $420 million from Teva Pharmaceutical Ind Ltd [8]

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

NEW YORK, Oct. 31, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=110021&from=4 CLASS PERIOD: F ...

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/edwards-lifescie ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Edwards Lifesciences Corporation (NYSE: EW). Shareholders who purchased shares of EW during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/edwards-lifesciences-loss-submission-form/?id=109666&from=3 CLASS PERIO ...

RADNOR, Pa., Oct. 29, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Edwards Lifesciences Corporation ("Edwards") (NYSE: EW) on behalf of investors who purchased or otherwise acquired Edwards securities between February 6, 2024 and July 24, 2024, inclusive (the "Class Period")  The lead plaintiff deadline is December 13, 2024.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Edw ...

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Edwards Lifesciences Corporation (NYSE:EW) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Edwards Lifesciences, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/edwards-lifesciences-corporation. Investors have until December 13, 2 ...

NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Edwards Lifesciences Corporation ("Edwards" or the "Company") (NYSE: EW) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Edwards investors who were adversely affected by alleged securities fraud between February 6, 2024 and July 24, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/edwards-lifesciences-l ...

SAN FRANCISCO, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Edwards Lifesciences Corporation (NYSE: EW) investors who suffered substantial losses to submit your losses now. Class Period: Feb. 6, 2024 – July 24, 2024Lead Plaintiff Deadline: Dec. 13, 2024 Visit: www.hbsslaw.com/investor-fraud/ew Contact the Firm Now: EW@hbsslaw.com 844-916-0895 Class Action Lawsuit Against Edwards Lifesciences Corporation (EW): The litigation is focused on the propriety of Edwards Lifesciences’ disclosures about its ...

Have you evaluated the performance of Edwards Lifesciences' (EW) international operations during the quarter that concluded in September 2024? Considering the extensive worldwide presence of this medical device maker, analyzing the patterns in international revenues is crucial for understanding its financial resilience and potential for growth.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and gr ...